Treatment for Patients Unsuitable for or Refractory to Conso

Tina Cascone, MD, Ben Levy, MD, and Sandip Patel, MD, offer insights into the treatment approach in patients with unresectable early-stage NSCLC who are unsuitable for consolidation durvalumab or who progress on consolidation durvalumab.

Related Keywords

Sandip Patel , Tina Cascone , , Recent Updates , Translating Evidence , Clinical Practice , Patients Unsuitable , Eben Levy , Nsclc , Early Nsclc , Non Small Cell Lung Cancer , Asco 2023 , Localized Disease , Presection , Surgery , Staging , Chemoimmunotherapy , Immunotherapy , Ohio , Molecular Testing , Liquid Biopsy , Tissue Biopsy , Ngs Testing , Egfr , Talk ,